Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Behav Brain Res ; 356: 120-126, 2019 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-30142397

RESUMEN

Aggressive behaviors can be considered symptoms of bipolar disorder, schizophrenia, post-traumatic stress, intermittent explosive, and personality disorders. Nociceptin/orphanin FQ (N/OFQ) is a peptide acting as endogenous ligand of the NOP receptor. Preclinical and clinical findings suggest the NOP receptor as an innovative target for the treatment of psychopathologies, such as anxiety, depression, and drug abuse. This study investigated the effects of NOP ligands and the behavioral phenotype of mice lacking the NOP receptor in an animal model of aggressiveness, the resident-intruder test. Mood stabilizers, such as valproate, lithium, and carbamazepine reduced aggressive behaviors of resident mice, while diazepam was inactive. In contrast, para-chlorophenylalanine (PCPA), an inhibitor of 5-HT synthesis, increased aggressiveness in mice. Similar to PCPA, the treatment with the NOP agonists Ro 65-6570 and AT-090 also increased aggressive behaviors. The systemic administration of the NOP antagonist SB-612111 did not modify the behavior of resident mice, but it prevented the aggressive behavior of Ro 65-6570. NOP receptor knockout mice did not display any behavioral difference compared to wild-type animals in the resident-intruder test. None of the treatments affected non-agonistic behaviors and spontaneous locomotion. In conclusion, NOP receptor agonists increased aggressiveness, while the pharmacological and genetic blockade of NOP receptor signaling did not modify agonistic behaviors. Ultimately, the aggressive profile of action of NOP agonists should be taken into account in the development of innovative psychiatric drugs targeting the NOP receptor.


Asunto(s)
Agresión/fisiología , Conducta Agonística/fisiología , Receptores Opioides/fisiología , Animales , Ansiedad , Trastorno Bipolar , Carbamazepina/farmacología , Cicloheptanos/farmacología , Depresión , Trastorno Depresivo , Modelos Animales de Enfermedad , Fenclonina/farmacología , Litio/farmacología , Masculino , Ratones , Ratones Noqueados , Péptidos Opioides/metabolismo , Piperidinas/farmacología , Receptores Opioides/agonistas , Receptores Opioides/genética , Ácido Valproico/farmacología , Receptor de Nociceptina , Nociceptina
2.
Molecules ; 22(8)2017 Aug 03.
Artículo en Inglés | MEDLINE | ID: mdl-28771213

RESUMEN

Depression is a disease that has affected a high proportion of the world's population and people of different ages, incapacitating them from good performance at work and in social relationships, and causing emotional disorders to millions of families. Therefore, the search for new therapeutic agents is considered a priority for the discovery of more effective forms of treatment. In this review, studies of essential oils and their constituents in experimental models related to depression are discussed. The mechanisms of action of the oils and the presence of psychoactive constituents in their chemical compositions are discussed. The data in the review show the therapeutic potential of essential oils and their chemical constituents for use in depressive disorders. Advanced studies using humans are needed to confirm the antidepressant properties described in animals.


Asunto(s)
Antidepresivos , Depresión/tratamiento farmacológico , Modelos Biológicos , Aceites Volátiles , Animales , Antidepresivos/química , Antidepresivos/uso terapéutico , Humanos , Aceites Volátiles/química , Aceites Volátiles/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...